191 related articles for article (PubMed ID: 31138787)
21. PCAT-1 contributes to cisplatin resistance in gastric cancer through epigenetically silencing PTEN via recruiting EZH2.
Li H; Ma X; Yang D; Suo Z; Dai R; Liu C
J Cell Biochem; 2020 Feb; 121(2):1353-1361. PubMed ID: 31478258
[TBL] [Abstract][Full Text] [Related]
22. Inhibition of MGMT-mediated autophagy suppression decreases cisplatin chemosensitivity in gastric cancer.
Lei Y; Tang L; Hu J; Wang S; Liu Y; Yang M; Zhang J; Tang B
Biomed Pharmacother; 2020 May; 125():109896. PubMed ID: 32007918
[TBL] [Abstract][Full Text] [Related]
23. RNF138 confers cisplatin resistance in gastric cancer cells via activating Chk1 signaling pathway.
Lu Y; Han D; Liu W; Huang R; Ou J; Chen X; Zhang X; Wang X; Li S; Wang L; Liu C; Miao S; Wang L; Ma C; Song W
Cancer Biol Ther; 2018; 19(12):1128-1138. PubMed ID: 30260263
[TBL] [Abstract][Full Text] [Related]
24. LAMA4 activated by Androgen receptor induces the cisplatin resistance in gastric cancer.
Peng L; Li Y; Wei S; Li X; Dang Y; Zhang W; Zhang G
Biomed Pharmacother; 2020 Apr; 124():109667. PubMed ID: 31958762
[TBL] [Abstract][Full Text] [Related]
25. PEA‑15 contributes to the clinicopathology and AKT‑regulated cisplatin resistance in gastric cancer.
Jiang X; Zhang C; Li W; Jiang D; Wei Z; Lv M; Xie X; Sun X
Oncol Rep; 2019 Mar; 41(3):1949-1959. PubMed ID: 30569123
[TBL] [Abstract][Full Text] [Related]
26. Synergism of rMV-Hu191 with cisplatin to treat gastric cancer by acid sphingomyelinase-mediated apoptosis requiring integrity of lipid raft microdomains.
Lv Y; Zhang CD; Wang YL; Zhou DM; Zhu MY; Hao XQ; Wang JH; Gu WZ; Shen HQ; Lou JG; Wu BQ; Chen PC; Zhao ZY
Gastric Cancer; 2021 Nov; 24(6):1293-1306. PubMed ID: 34251544
[TBL] [Abstract][Full Text] [Related]
27. The forkhead transcription factor FOXO1 mediates cisplatin resistance in gastric cancer cells by activating phosphoinositide 3-kinase/Akt pathway.
Park J; Ko YS; Yoon J; Kim MA; Park JW; Kim WH; Choi Y; Kim JH; Cheon Y; Lee BL
Gastric Cancer; 2014; 17(3):423-30. PubMed ID: 24202965
[TBL] [Abstract][Full Text] [Related]
28. PAK4 confers cisplatin resistance in gastric cancer cells via PI3K/Akt- and MEK/ERK-dependent pathways.
Fu X; Feng J; Zeng D; Ding Y; Yu C; Yang B
Biosci Rep; 2014 Apr; 34(2):. PubMed ID: 27919028
[TBL] [Abstract][Full Text] [Related]
29. Combining α-Hederin with cisplatin increases the apoptosis of gastric cancer in vivo and in vitro via mitochondrial related apoptosis pathway.
Deng H; Ma J; Liu Y; He P; Dong W
Biomed Pharmacother; 2019 Dec; 120():109477. PubMed ID: 31562979
[TBL] [Abstract][Full Text] [Related]
30. Adipose most abundant 2 protein is a predictive marker for cisplatin sensitivity in cancers.
Kamimura K; Suda T; Fukuhara Y; Okuda S; Watanabe Y; Yokoo T; Osaki A; Waguri N; Ishikawa T; Sato T; Aoyagi Y; Takamura M; Wakai T; Terai S
Sci Rep; 2021 Mar; 11(1):6255. PubMed ID: 33737617
[TBL] [Abstract][Full Text] [Related]
31. MicroRNA-421 regulated by HIF-1α promotes metastasis, inhibits apoptosis, and induces cisplatin resistance by targeting E-cadherin and caspase-3 in gastric cancer.
Ge X; Liu X; Lin F; Li P; Liu K; Geng R; Dai C; Lin Y; Tang W; Wu Z; Chang J; Lu J; Li J
Oncotarget; 2016 Apr; 7(17):24466-82. PubMed ID: 27016414
[TBL] [Abstract][Full Text] [Related]
32. Forkhead Box Protein C2 (FOXC2) Promotes the Resistance of Human Ovarian Cancer Cells to Cisplatin In Vitro and In Vivo.
Li C; Ding H; Tian J; Wu L; Wang Y; Xing Y; Chen M
Cell Physiol Biochem; 2016; 39(1):242-52. PubMed ID: 27336949
[TBL] [Abstract][Full Text] [Related]
33. HIF-1α-dependent miR-424 induction confers cisplatin resistance on bladder cancer cells through down-regulation of pro-apoptotic UNC5B and SIRT4.
Yu M; Ozaki T; Sun D; Xing H; Wei B; An J; Yang J; Gao Y; Liu S; Kong C; Zhu Y
J Exp Clin Cancer Res; 2020 Jun; 39(1):108. PubMed ID: 32522234
[TBL] [Abstract][Full Text] [Related]
34. Apoptin-derived peptide reverses cisplatin resistance in gastric cancer through the PI3K-AKT signaling pathway.
Zhou D; Liu W; Liang S; Sun B; Liu A; Cui Z; Han X; Yuan L
Cancer Med; 2018 Apr; 7(4):1369-1383. PubMed ID: 29522284
[TBL] [Abstract][Full Text] [Related]
35. Adenovirus-mediated IL-24 expression enhances the chemosensitivity of multidrug-resistantgastric cancer cells to cisplatin.
Mao Z; Bian G; Sheng W; He S; Yang J; Dong X
Oncol Rep; 2013 Nov; 30(5):2288-96. PubMed ID: 23982423
[TBL] [Abstract][Full Text] [Related]
36. Down-regulation of CCNE1 expression suppresses cell proliferation and sensitizes gastric carcinoma cells to Cisplatin.
Zhang C; Zhu Q; Gu J; Chen S; Li Q; Ying L
Biosci Rep; 2019 Jun; 39(6):. PubMed ID: 31072916
[TBL] [Abstract][Full Text] [Related]
37. PCAT-1 contributes to cisplatin resistance in gastric cancer through miR-128/ZEB1 axis.
Guo Y; Yue P; Wang Y; Chen G; Li Y
Biomed Pharmacother; 2019 Oct; 118():109255. PubMed ID: 31352238
[TBL] [Abstract][Full Text] [Related]
38. Folate receptor α increases chemotherapy resistance through stabilizing MDM2 in cooperation with PHB2 that is overcome by MORAb-202 in gastric cancer.
Sakai H; Kawakami H; Teramura T; Onodera Y; Somers E; Furuuchi K; Uenaka T; Kato R; Nakagawa K
Clin Transl Med; 2021 Jun; 11(6):e454. PubMed ID: 34185411
[TBL] [Abstract][Full Text] [Related]
39. The effects and mechanism of α-mangostin on chemosensitivity of gastric cancer cells.
Li RR; Zeng DY
Kaohsiung J Med Sci; 2021 Aug; 37(8):709-717. PubMed ID: 34003591
[TBL] [Abstract][Full Text] [Related]
40. MiR-129 reduces CDDP resistance in gastric cancer cells by inhibiting MAPK3.
Cao HY; Xiao CH; Lu HJ; Yu HZ; Hong H; Guo CY; Yuan JF
Eur Rev Med Pharmacol Sci; 2019 Aug; 23(15):6478-6485. PubMed ID: 31378887
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
